Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AVITA MED LTD/S stock logo
AVMXY
AVITA MED LTD/S
$7.89
$7.89
$1.06
$8.58
$651.87M1.28183,275 shsN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
$15.80
-0.4%
$15.07
$12.72
$34.47
$2.70B0.611.21 million shs1.91 million shs
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$5.03
-1.6%
$4.92
$3.79
$12.36
$2.04B0.8415.42 million shs32.01 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$34.64
-3.5%
$33.73
$27.12
$60.90
$2.08B2.38970,850 shs1.49 million shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AVITA MED LTD/S stock logo
AVMXY
AVITA MED LTD/S
0.00%0.00%0.00%0.00%0.00%
Immunovant, Inc. stock logo
IMVT
Immunovant
0.00%+0.89%+9.27%-18.72%-42.17%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
0.00%+2.24%+23.28%-25.92%-43.16%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.00%+3.34%+22.58%-22.92%-32.04%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AVITA MED LTD/S stock logo
AVMXY
AVITA MED LTD/S
N/AN/AN/AN/AN/AN/AN/AN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
0.9394 of 5 stars
3.50.00.00.00.01.70.0
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
1.8085 of 5 stars
3.21.00.00.02.61.70.6
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
4.1057 of 5 stars
4.41.00.04.42.20.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AVITA MED LTD/S stock logo
AVMXY
AVITA MED LTD/S
0.00
N/AN/AN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
2.90
Moderate Buy$38.33142.62% Upside
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
2.33
Hold$7.0039.17% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$50.4045.50% Upside

Current Analyst Ratings Breakdown

Latest AVMXY, IMVT, TWST, and RXRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/16/2025
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $5.00
5/6/2025
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$11.00 ➝ $8.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $48.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$54.00 ➝ $44.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$40.00 ➝ $33.00
4/22/2025
Immunovant, Inc. stock logo
IMVT
Immunovant
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$38.00 ➝ $17.00
4/10/2025
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$10.00 ➝ $8.00
4/10/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$58.00 ➝ $45.00
4/8/2025
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
3/28/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$50.00
(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AVITA MED LTD/S stock logo
AVMXY
AVITA MED LTD/S
$5.51M118.31N/AN/A$0.26 per share30.35
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/A$4.16 per shareN/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$58.84M34.75N/AN/A$2.61 per share1.93
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$312.97M6.63N/AN/A$8.07 per share4.29
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AVITA MED LTD/S stock logo
AVMXY
AVITA MED LTD/S
-$24.75M-$0.39N/AN/AN/AN/AN/AN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
-$413.84M-$2.74N/AN/AN/AN/A-80.60%-71.89%8/5/2025 (Estimated)
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$463.66M-$1.77N/AN/AN/A-961.32%-74.70%-54.02%8/6/2025 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$3.25N/AN/AN/A-54.98%-33.48%-25.34%8/1/2025 (Estimated)

Latest AVMXY, IMVT, TWST, and RXRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/29/2025Q4 2025
Immunovant, Inc. stock logo
IMVT
Immunovant
-$0.72-$0.64+$0.08-$0.64N/A$0.16 million
5/5/2025Q1 2025
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$0.44-$0.50-$0.06-$0.50$18.12 million$14.75 million
5/5/2025Q2 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.56-$0.66-$0.10-$0.66$92.00 million$92.79 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AVITA MED LTD/S stock logo
AVMXY
AVITA MED LTD/S
N/AN/AN/AN/AN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/AN/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AVITA MED LTD/S stock logo
AVMXY
AVITA MED LTD/S
N/A
5.50
5.33
Immunovant, Inc. stock logo
IMVT
Immunovant
N/A
11.16
11.16
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
0.02
4.11
4.11
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
4.51
4.24

Institutional Ownership

CompanyInstitutional Ownership
AVITA MED LTD/S stock logo
AVMXY
AVITA MED LTD/S
0.01%
Immunovant, Inc. stock logo
IMVT
Immunovant
47.08%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
89.06%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
AVITA MED LTD/S stock logo
AVMXY
AVITA MED LTD/S
N/A
Immunovant, Inc. stock logo
IMVT
Immunovant
5.90%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
8.43%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
AVITA MED LTD/S stock logo
AVMXY
AVITA MED LTD/S
5582.62 millionN/ANot Optionable
Immunovant, Inc. stock logo
IMVT
Immunovant
120170.92 million160.84 millionOptionable
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
400406.49 million372.23 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99059.92 million58.11 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVITA MED LTD/S stock logo

AVITA MED LTD/S OTCMKTS:AVMXY

Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products for the treatment of burns, chronic wounds, and aesthetics indications. The company's patented and proprietary collection and application technology provides treatment solutions derived from a patient's own skin. Its lead product, RECELL System, is used in the treatment of various skin defects, such as burns and plastic reconstructive procedures. The company also offers ReGenerCell for chronic wounds and ReNovaCell for the restoration of pigmentation. Avita Medical Limited is based in Valencia, California.

Immunovant stock logo

Immunovant NASDAQ:IMVT

$15.80 -0.06 (-0.38%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$15.80 0.00 (0.00%)
As of 06/20/2025 05:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Recursion Pharmaceuticals stock logo

Recursion Pharmaceuticals NASDAQ:RXRX

$5.03 -0.08 (-1.57%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$5.02 -0.01 (-0.18%)
As of 06/20/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$34.64 -1.25 (-3.48%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$35.43 +0.79 (+2.28%)
As of 06/20/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.